Challenge: hepatitis C transmission among persons who inject drugs.
Globally, about 50 per cent of persons who inject drugs have been infected with hepatitis C virus (HCV). Prevention requires access to harm-reduction services, i.e., sterile needles, opioid substitution therapy and testing and treatment for hepatitis C. Yet only a few countries (e.g., Australia, Canada) provide adequate harm-reduction services, underscoring the need for greater investment and political will to protect populations most vulnerable to hepatitis C.


Comments
Post a Comment